Prostate Cancer: Active Surveillance COE - Results from #10

REVIEW UroToday

Prostate Cancer: Active Surveillance COE

Search

2024 NCCN Guidelines: Simplifying the Management of Very Low-Risk Prostate Cancer - Rashid Sayyid & Zachary Klaassen Details Rashid Sayyid and Zach Klaassen review the 2024 NCCN Guidelines for managing very low-risk prostate cancer. Dr. Sayyid defines very low-risk prostate cancer using criteria like T1C stage, PSA levels, and biopsy characteristics. The updated guidelines simplify management based on life expectancy: patients with 10 years or more are recommended active surveillance, while those with less are advised o...
MAST Trial: Investigating Metformin's Role in Prostate Cancer Active Surveillance - Anthony Joshua Details Anthony Joshua presents the findings of the MAST trial, a decade-long investigation into the use of metformin for men with low-risk prostate cancer under active surveillance. Conducted across 12 Canadian centers, this randomized Phase III study involved 408 men and aimed to determine if metformin could delay cancer progression. Despite earlier promising studies suggesting potential benefits, the t...
The Use of Imaging in Staging Localized Prostate Cancer: A Case Study on High-Risk Localized Prostate Cancer - Zachary Klaassen Details Program: State-of-the-Art Interdisciplinary Management of Prostate Cancer. This series is part of an Independent Medical Education Initiative Supported by BAYER U.S. LLC PHARMACEUTICALS Biographies: Zachary Klaassen, MD, MSc, Urologic Oncologist, Assistant Professor Surgery/Urology at the Medical College of Georgia at Augusta University, Well Star MCG, Georgia Cancer Center, Augusta, GA Neal D. Sh...
Best Practices for Active Surveillance "Presentation" - Benjamin Lowentritt, Ronney Abaza, Aaron Berger, David Crawford, & David Morris Details Benjamin Lowentritt leads a panel discussion on active surveillance for prostate cancer, with a focus on appropriate patient selection, adherence monitoring, and determining triggers to stop surveillance and pursue treatment. The experts emphasize that most low risk patients should be offered active surveillance and monitored closely, though debate exists around including favorable intermediate ri...